Literature DB >> 28214140

A review of strategies for infarct size reduction during acute myocardial infarction.

Yasir Parviz1, Sethumadhavan Vijayan2, Shahar Lavi3.   

Abstract

Advances in medical and interventional therapy over the last few decades have revolutionized the treatment of acute myocardial infarction. Despite the ability to restore epicardial coronary artery patency promptly through percutaneous coronary intervention, tissue level damage may continue. The reported 30-day mortality after all acute coronary syndromes is 2 to 3%, and around 5% following myocardial infarction. Post-infarct complications such as heart failure continue to be a major contributor to cardiovascular morbidity and mortality. Inadequate microvascular reperfusion leads to worse clinical outcomes and potentially strategies to reduce infarct size during periods of ischemia-reperfusion can improve outcomes. Many strategies have been tested, but no single strategy alone has shown a consistent result or benefit in large scale randomised clinical trials. Herein, we review the historical efforts, current strategies, and potential novel concepts that may improve myocardial protection and reduce infarct size.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Infarct size; Myocardial infarction; Reperfusion

Mesh:

Year:  2017        PMID: 28214140     DOI: 10.1016/j.carrev.2017.02.004

Source DB:  PubMed          Journal:  Cardiovasc Revasc Med        ISSN: 1878-0938


  4 in total

1.  Diallyl trisulfide exerts cardioprotection against myocardial ischemia-reperfusion injury in diabetic state, role of AMPK-mediated AKT/GSK-3β/HIF-1α activation.

Authors:  Liming Yu; Wencheng Di; Xue Dong; Zhi Li; Xiaodong Xue; Jian Zhang; Qi Wang; Xiong Xiao; Jinsong Han; Yang Yang; Huishan Wang
Journal:  Oncotarget       Date:  2017-08-24

2.  Synthetic CpG oligonucleotides induce a genetic profile ameliorating murine myocardial I/R injury.

Authors:  Tobias Hilbert; Paul Markowski; Stilla Frede; Olaf Boehm; Pascal Knuefermann; Georg Baumgarten; Andreas Hoeft; Sven Klaschik
Journal:  J Cell Mol Med       Date:  2018-04-19       Impact factor: 5.310

3.  Augmented glycaemic gap is a marker for an increased risk of post-infarct left ventricular systolic dysfunction.

Authors:  Yong Zhu; Kesen Liu; Shuai Meng; Ruofei Jia; Xuan Lei; Maolin Chen; Kaiyuan Zou; Huagang Zhu; Zening Jin
Journal:  Cardiovasc Diabetol       Date:  2020-07-04       Impact factor: 9.951

4.  The effects of Anisodamine-Tirofiban Combined Therapy in acute myocardial infarction treated with Percutaneous Coronary Intervention (PCI).

Authors:  Yan Jiao; Xiaoying Fu; Qingxin Liu; Wei Zhang
Journal:  Pak J Med Sci       Date:  2022 Sep-Oct       Impact factor: 2.340

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.